Mineralys Therapeutics, Inc./$MLYS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
- Ticker
- $MLYS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Radnor, United States
- Website
- mineralystx.com
MLYS Metrics
BasicAdvanced
$1.6B
-
-$4.38
0.67
-
Price and volume
Market cap
$1.6B
Beta
0.67
52-week high
$47.65
52-week low
$18.11
Average daily volume
1.5M
Financial strength
Current ratio
34.464
Quick ratio
34.236
Long term debt to equity
0.177
Total debt to equity
0.177
Profitability
EBITDA (TTM)
-370.752
Management effectiveness
Return on assets (TTM)
-46.18%
Return on equity (TTM)
-80.88%
Valuation
Price to book
2.92
Price to tangible book (TTM)
2.92
Price to free cash flow (TTM)
-10.462
Free cash flow yield (TTM)
-9.56%
Free cash flow per share (TTM)
-1.738
Growth
Earnings per share change (TTM)
25.30%
3-year earnings per share growth (CAGR)
26.51%
What the Analysts think about MLYS
Analyst ratings (Buy, Hold, Sell) for Mineralys Therapeutics, Inc. stock.
Analyst projections of the future price of Mineralys Therapeutics, Inc. stock.
Bulls say / Bears say
In the Phase 3 Launch-HTN analysis, lorundrostat lowered systolic blood pressure in difficult-to-treat patients with chronic kidney disease by 9.6 mmHg versus placebo at 12 weeks. That supports its potential as an add-on treatment for a large group still struggling to control blood pressure. (Reuters)
A small Phase 2 CKD study found a significant reduction in urine albumin, a marker of kidney damage, as well as lower blood pressure. If larger, longer studies confirm this signal, lorundrostat could have value beyond blood-pressure control. (Kidney International)
The FDA has accepted lorundrostat’s application and set a 22 December 2026 decision date, while Mineralys says its cash and investments should fund operations, including a potential launch, into 2028. This gives the company a near-term regulatory catalyst and time to prepare commercially without an immediate need for more capital. (Mineralys Therapeutics)
Mineralys has no marketed product, and its business depends on lorundrostat; the FDA is still reviewing the application. A rejection or delay could leave the company without a source of product revenue and force it to seek more funding. (SEC)
The CKD study involved only 59 people and lasted four weeks, so it cannot establish durable kidney or cardiovascular benefit. Kidney function fell during treatment, and some participants stopped because of adverse events, including hyperkalaemia and worsening CKD. (Kidney International)
Lorundrostat could enter behind AstraZeneca’s already-approved same-class drug, baxdrostat. ICER found the short-term evidence for lorundrostat versus established treatments inconclusive or comparable to inferior, while cardiovascular benefits have not been demonstrated, which could make differentiation and payer access harder. (ICER, AllSci)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
MLYS Financial Performance
Revenues and expenses
MLYS Earnings Performance
Company profitability
Upcoming events
No upcoming events
MLYS News
AllArticlesVideos
Funds containing MLYS
Fund name | Fund size | $MLYS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.12% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.12% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.04% |
iShares MSCI World Small Cap£WLDS | $9B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.